OmniAb Q2 FY26 net loss narrows to $5.86 million; revenue more than doubled to $13.42 million
OABI•Costs, outlook and partner activity
Cash costs and operating expenses (non-GAAP) rose to $13.3 million from $11.9 million; total GAAP costs and operating expenses were flat at $20.1 million.
OmniAb raised its 2026 revenue outlook to $32 million-$36 million and lifted its year-end cash and cash equivalents forecast to $37 million-$41 million.
The quarter included new license agreements with EnRosa Therapeutics and argenx; OmniAb said it had 110 active partners and 425 active programs, including 34 in clinical development.
Q2 revenue more than doubles on milestone revenue
OmniAb posted Q2 revenue of $13.4 million, more than doubled from the year-earlier period, driven primarily by milestone revenue.
Net loss narrowed to $5.9 million, or $0.05 per share, from $15.9 million, or $0.15 per share, a year earlier.
